A Phase II Single Arm Trial of BIBW 2992 in non small cell lung cancer patients with activating EGFR mutations
|Effective start/end date||3/27/07 → 6/30/13|
- Boehringer-Ingelheim Pharmaceuticals
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.